From Clinical Practice to Basic Science, in Search for the Ideal Implantable Bioreactor: A Review on MFAT (Micro-Fragmented Adipose Tissue-Lipogems ® ) Biology and Its Clinical Applications.
Tremolada C., Alessandri G.
Narrative Review, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Int J Mol Sci (2026)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42449985
- DOI
- 10.3390/ijms27135710
Abstract (original English)
The therapeutic use of adipose tissue has evolved from volumetric replacement to biologically driven regenerative applications. This brief review analyzes micro-fragmented adipose tissue (MFAT), obtained through Lipogems ® technology, as a paradigmatic example of reverse translation in regenerative medicine, where consistent clinical efficacy preceded and guided mechanistic investigation. Unlike enzymatic digestion or aggressive mechanical emulsification (nanofat), Lipogems ® device processing preserves the native stromal vascular niche, including extracellular matrix architecture and the pericyte-endothelial complex. We review the biological mechanisms underlying MFAT activity, compare MFAT with stromal vascular fraction (SVF) and nanofat, summarize consolidated clinical evidence across multiple medical and surgical specialties, and discuss emerging translational applications in oncology and sepsis. Collectively, the available data position MFAT as a structurally intact, biologically responsive tissue bioreactor bridging clinical practice and regenerative biology.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.